drugs glp 1 GLP-1 Weight Loss Options List of approved and pending

Sterne JA, Hernn MA, Reeves BC, et al

When BMI and comorbidity thresholds are met for anti obesity pharmacotherapy, GLP-1 agonists are recommended as first line or preferred pharmacologic options because of superior weight loss efficacy and cardiometabolic benefit

Retatrutide represents a promising pipeline compound that could expand the therapeutic toolkit, especially for patients with concurrent MASLD/MASH where glucagon-mediated hepatic fat oxidation may provide additional benefit

Survodutide is another dual agonist in development, targeting GLP-1 and glucagon receptors

This hormone-based mechanism affects multiple metabolic pathways simultaneously, which explains its more pronounced appetite suppression compared to older medications

Of the 53 100 eligible for inclusion, 2003 were identified as GLP1 RA initiators, and 51 097 were identified as metformin users